Search
Search Results
##search.searchResults.foundPlural##
-
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3569PDF: 2110HTML: 7589 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1452PDF: 1164HTML: 280 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7991PDF: 2538HTML: 2176Table 1.: 278Table 2.: 296Table 3.: 267Table 4.: 268 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3648PDF: 1493HTML: 2747 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2721PDF: 922HTML: 9076Efremov 1: 278Efremov 2: 247 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3660PDF: 2382HTML: 23657Untitled: 322Untitled: 297Untitled: 315 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
2131PDF: 876HTML: 672 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1540PDF: 877HTML: 1042 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2763PDF: 1751HTML: 2466Table1: 290 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4782PDF: 1753HTML: 4353Tables and Images: 301 -
VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS
3997PDF: 1697HTML: 8270Randi Fig: 235 -
MAGNUSIOMYCES CAPITATUS BREAKTHROUGH INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RECEIVING ECHINOCANDIN PROPHYLAXIS: CLINICAL FEATURES, MANAGEMENT, AND REVIEW OF THE LITERATURE
177PDF: 239Suppl. Files: 45Html: 121Html Suppl. Files: 109 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1647PDF: 998Suppl. Files: 498HTML: 308 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
3093PDF: 1465HTML: 3746Untitled: 264Untitled: 263Untitled: 220 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2154PDF: 2045HTML: 813 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1742PDF: 841HTML: 4432Figure 1: 199Untitled: 190Untitled: 246 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
1111PDF: 598HTML: 350 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2506PDF: 813HTML: 2159Untitled: 293Untitled: 201Untitled: 234Untitled: 215Untitled: 232Untitled: 248Untitled: 236 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3672PDF: 1377HTML: 2416Fi.1 Gritti.Rambaldi: 264 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1786PDF: 1160HTML: 511 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2542PDF: 1089HTML: 1679Fig 1: 271Tab I: 263Cover Letter: 272 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4163PDF: 1139HTML: 3919Untitled: 205Cneo. Fig.1: 147Untitled: 138Untitled: 173Untitled: 175







